|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01083719 |
|
Date of registration:
|
06/03/2010 |
|
Primary sponsor: |
|
|
Public title:
|
A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
|
|
Scientific title:
|
Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes. |
|
Date of first enrolment:
|
April 2010 |
|
Target sample size:
|
15 |
|
Recruitment status: |
Not yet recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01083719 |
|
Study type:
|
Interventional |
|
Study design:
|
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Post operative patients of documented high grade gliomas (grade III and IV)
2. Patients who have not undergone any previous irradiation to brain.
3. Performance Scale as defined by ECOG PS 0-3
Exclusion Criteria:
1. Patients who are diabetic.
2. Patients who are pregnant.
3. Any documented contrast allergy to the agents used for imaging.
4. Patients who are unable to comprehend or cooperate effectively for treatment
planning.
Age minimum:
18 Years
Age maximum:
70 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Glioblastoma
|
|
Intervention(s)
|
|
Procedure: FDG-PET
|
|
Primary Outcome(s)
|
|
Tumor infiltration defined on FDG-PET not determined to MRI
[Time Frame: 18 months]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|